Tracking a new Alzheimer's drug: does it help and is it safe?
NCT ID NCT06741553
Summary
This study aims to closely watch 120 people with early Alzheimer's disease who are taking the drug lecanemab. Researchers will track changes in their brain scans, memory, thinking, and daily life over 18 months to see how well the drug works and monitor for any side effects. The goal is to better understand the real-world benefits and risks of this newer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital, School of Medicine, Zhejiang University, China
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.